BHC.TO - Bausch Health Companies Inc.

Toronto - Toronto Delayed Price. Currency in CAD
28.38
-1.02 (-3.47%)
At close: 4:17PM EDT
Stock chart is not supported by your current browser
Previous Close29.40
Open29.08
Bid28.33 x 0
Ask28.34 x 0
Day's Range28.25 - 29.45
52 Week Range23.60 - 36.52
Volume675,367
Avg. Volume643,196
Market Cap9.997B
Beta (3Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2010-11-10
1y Target EstN/A
All
News
Press Releases
  • PR Newswire

    Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-123 Treatment For Acne Vulgaris In Lotion Form

    PDUFA Action Date is Dec. 22, 2019 LAVAL, Quebec , Aug. 7, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription ...

  • PR Newswire

    Bausch Health Companies Inc. Announces Second-Quarter 2019 Results And Raises Full-Year Guidance

    LAVAL, Quebec , Aug. 6, 2019 /PRNewswire/ -- Second-Quarter 2019 Financial Results Revenues of $2.152 Billion GAAP Net Loss of $171 Million Adjusted EBITDA (non-GAAP) 1  of $880 Million GAAP Cash Flow ...

  • PR Newswire

    Bausch Health Expands Dermatology Cash-Pay Prescription Program to Walgreens Stores Nationwide

    DEERFIELD, Ill. and LAVAL, Quebec, Aug. 1, 2019 /PRNewswire/ -- Walgreens and Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") today announced a modification to their existing fulfillment agreement to bring patients lower prices, increased transparency and convenience for many of Bausch Health's dermatology products. Under the expanded agreement, Walgreens patients will have access to select dermatology products from Bausch Health's first-of-its-kind cash-pay prescription program, Dermatology.com, at lower flat cash rates ranging from $50-$115.

  • PR Newswire

    Bausch Health Provides APRISO® Intellectual Property Litigation Update

    BRIDGEWATER, N.J., July 31, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") along with its wholly owned subsidiary, Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, have agreed to resolve the outstanding intellectual property litigation with Teva Pharmaceuticals USA, Inc. ("Teva") regarding APRISO® (mesalamine) extended-release capsules 0.375g.

  • PR Newswire

    Bausch Health to Reduce Debt by Additional $100 Million Using Cash Flow from Operations

    LAVAL, Quebec, July 29, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it put in notice to pay down an additional $100 million of its senior secured term loans this week, using cash flow from operations. After this payment, the Company will have paid all mandatory amortization through the second quarter of 2020. Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products.

  • PR Newswire

    Court Upholds The Validity And Determined Actavis' Infringement Of Patent Protecting RELISTOR® Tablets

    BRIDGEWATER, N.J. and NEW YORK, July 17, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") and Progenics Pharmaceuticals (PGNX), announced today that the U.S. District Court of New Jersey upheld the validity and determined Actavis' infringement of a patent protecting RELISTOR® (methylnaltrexone bromide) tablets, expiring March 2031. Defendant, Actavis Laboratories FL, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd, had challenged the validity of and had alleged non-infringement of Claims 2 and 5 of U.S. Patent No. 8,524,276, which protects the formulation of RELISTOR® tablets.

  • PR Newswire

    Bausch + Lomb Announces U.S. Launch Of Ocuvite® Eye Performance Vitamins

    BRIDGEWATER, N.J., July 9, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TXS: BHC), today announced the U.S. launch of Ocuvite® Eye Performance vitamins, a nutritional supplement designed to meet the changing needs of consumers while further expanding the company's eye vitamin portfolio. "Today's modern, always-on world has evolved faster than our eyes – from the blue light of computer screens and cell phones to the increased UV exposure from the sun – which can have an impact on our eye health," said Joe Gordon, U.S. president, Bausch + Lomb.

  • PR Newswire

    Bausch Health Companies Inc. Will Release Second-Quarter 2019 Financial Results On August 6

    LAVAL, Quebec , July 8, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its second-quarter 2019 financial results on Tuesday, Aug. 6, 2019 . Bausch ...

  • PR Newswire

    Bausch Health To Reduce Debt By Additional $100 Million Using Cash Generated From Operations

    LAVAL, Quebec, June 25, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it put in notice to pay down an additional $100 million of its senior secured term loans this week, using cash generated from operations. After this payment, the Company will have eliminated all mandatory amortization for the first quarter of 2020. Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products.

  • PR Newswire

    Bausch Health Announces U.S. Launch of DUOBRII™ (halobetasol propionate and tazarotene) Lotion 0.01%/0.045% for Plaque Psoriasis in Adults

    LAVAL, Quebec, June 25, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) and its dermatology business, Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that DUOBRII™ (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045%, will be available commercially to health care professionals starting this week. Approved by the U.S. Food and Drug Administration on April 25, 2019, DUOBRII is the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene in one formulation. "The launch of DUOBRII marks the fifth innovative therapy that Ortho Dermatologics has brought forward within the last 30 months," said Bill Humphries, president, Ortho Dermatologics.

  • PR Newswire

    Bausch + Lomb ULTRA® Multifocal for Astigmatism Contact Lenses Now Available In the United States

    BRIDGEWATER, N.J., June 19, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (NYSE/TXS: BHC), today announced the U.S. launch of Bausch + Lomb ULTRA® Multifocal for Astigmatism contact lenses, the first and only multifocal toric lens available as a standard offering in the eye care professional's fit set. The new monthly silicone hydrogel lens, which was specifically designed to address the lifestyle and vision needs of patients with both astigmatism and presbyopia, combines the company's unique 3-Zone Progressive™ multifocal design with the stability of its OpticAlign® toric design to provide eye care professionals and their patients an advanced contact lens technology that offers the convenience of same-day fitting during the initial lens exam.

  • PR Newswire

    Bausch Health Companies Announces Participation in Upcoming Investor Conferences

    LAVAL, Quebec , May 29, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that the Company will participate in two investor conferences in June. Paul S. Herendeen , executive ...

  • PR Newswire

    Bausch Health Announces Early Tender Results and Early Settlement Date for Cash Tender Offers for Senior Notes

    LAVAL, Quebec, May 23, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health," the "Company" or the "Offeror") announced today the results to date of its pending cash tender offers (collectively, the "Tender Offers," and each offer to purchase a series of notes individually, a "Tender Offer") to purchase up to $1,500,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of its outstanding notes listed in the table below (collectively, the "Notes"), as well as the anticipated early settlement date for the Tender Offers on May 24, 2019 (the "Early Settlement Date"). The terms and conditions of the Tender Offers are described in an Offer to Purchase dated May 9, 2019 (as it may be amended or supplemented from time to time, the "Offer to Purchase") and the related Letter of Transmittal.

  • PR Newswire

    Bausch Health Announces Pricing Of Private Offering Of Senior Notes

    LAVAL, Quebec, May 9, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has priced its previously announced offering of $750,000,000 aggregate principal amount of 7.000% senior notes due 2028 (the "2028 Notes") and $750,000,000 aggregate principal amount of 7.250% senior notes due 2029 (the "2029 Notes" and, together with the 2028 Notes, the "Notes"). The 2028 Notes will be sold to investors at a price of 100.00% of the principal amount thereof and the 2029 Notes will be sold to investors at a price of 100.00% of the principal amount thereof. Bausch Health intends to use the net proceeds from the offering of the Notes, along with cash on hand, to repurchase $1,500 million aggregate principal amount across the Company's outstanding 5.50% Senior Notes due 2023 (the "5.50% Notes") and 5.875% Senior Notes due 2023 (the "5.875% Notes" and, together with the 5.50% Notes, the "Existing Notes"), pursuant to its previously announced tender offers, and to pay related fees and expenses.

  • PR Newswire

    Bausch Health Commences Cash Tender Offers For Up To $1,500,000,000 Aggregate Principal Amount Of Outstanding Notes Of Certain Series

    LAVAL, Quebec, May 9, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health," the "Company" or the "Offeror") announced today that it has commenced cash tender offers (collectively, the "Tender Offers," and each offer to purchase a series of notes individually, a "Tender Offer") to purchase up to $1,500,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of its outstanding notes listed in the table below (collectively, the "Notes"). The terms and conditions of the Tender Offers are described in an Offer to Purchase dated May 9, 2019 (as it may be amended or supplemented from time to time, the "Offer to Purchase") and the related Letter of Transmittal.

  • PR Newswire

    Bausch Health Announces Launch Of Private Offering Of Senior Notes

    LAVAL, Quebec, May 9, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has launched an offering of $750,000,000 aggregate principal amount of senior notes due 2028 (the "2028 Notes") and $750,000,000 aggregate principal amount of senior notes due 2029 (the "2029 Notes" and, together with the 2028 Notes, the "Notes"). Bausch Health intends to use the net proceeds from the offering of the Notes, along with cash on hand, to repurchase $1,500 million aggregate principal amount across the Company's outstanding 5.50% Senior Notes due 2023 (the "5.50% Notes") and 5.875% Senior Notes due 2023 (the "5.875% Notes" and, together with the 5.50% Notes, the "Existing Notes") pursuant to tender offers announced today, and to pay related fees and expenses.

  • PR Newswire

    Bausch Health Companies Inc. Announces First-Quarter 2019 Results And Raises Full-Year Guidance

    LAVAL, Quebec , May 6, 2019 /PRNewswire/ -- First-Quarter 2019 Financial Results Revenues of $2.016 Billion GAAP Net Loss of $52 Million GAAP Cash Flow From Operations of $413 Million in line with Company ...

  • PR Newswire

    Bausch Health Issues Form 8K For 2019 Annual Meeting Of Shareholders Presentation

    LAVAL, Quebec , April 30, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") today announced Bausch Health Companies Inc. (the "Company") is providing ...

  • PR Newswire

    Bausch + Lomb Announces New Scientific Analyses Featuring Surgical And Pharmaceutical Products Will Be Presented During The Annual Meeting Of The American Society Of Cataract And Refractive Surgery

    A Total of 26 Podium Presentations and Posters to be Featured BRIDGEWATER, N.J. , April 29, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch ...

  • PR Newswire

    New Scientific And Clinical Analyses Regarding Bausch + Lomb Surgical And Pharmaceutical Products To Be Presented During The Association For Research In Vision And Ophthalmology Meeting

    Data from the Company's Antibiotic Resistance Monitoring in Ocular MicRoorganisms (ARMOR) Study will also be Featured BRIDGEWATER, N.J. , April 26, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global ...

  • CNW Group

    IIROC Trade Resumption - BHC

    IIROC Trade Resumption - BHC

  • PR Newswire

    FDA Approves Bausch Health's DUOBRII™ (Halobetasol Propionate And Tazarotene) Lotion 0.01%/0.045% For Plaque Psoriasis In Adults

    First and Only Topical Lotion Combining Halobetasol Propionate and Tazarotene in One Formulation(1) Safety was Established in a Long-Term Study of Up to 24 Weeks of Continuous Use and Up to 52 Weeks of ...

  • CNW Group

    IIROC Trading Halt - BHC

    IIROC Trading Halt - BHC

  • PR Newswire

    Salix Enters Into Exclusive License Agreement With Mitsubishi Tanabe Pharma To Develop And Commercialize Late Stage Investigational S1P Modulator For The Treatment Of Inflammatory Bowel Disease

    Investigational Oral Compound to Strengthen Salix's Expanding Pipeline BRIDGEWATER, N.J. , April 25, 2019 /PRNewswire/ -- Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical ...

  • PR Newswire

    Bausch Health Companies Announces Participation In Upcoming Investor Conferences

    LAVAL, Quebec , April 24, 2019 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that the Company will participate in four investor conferences in May. Paul S. Herendeen , executive ...